The Overview: February 2024

OCRA Harnessing Artificial Intelligence to Develop Blood Test to Detect Ovarian Cancer

In a news segment for NBC 4 New York, Dr. Daniel Heller, an OCRA grantee, discussed the exciting OCRA-funded study being undertaken in partnership with Microsoft AI for Health.  

“We’re really excited about the power of AI because there has been so much success in other disease areas, and because we have this great partnership with Microsoft,” says Audra Moran, OCRA’s President & CEO. “We think there’s so much potential.”

Dr. Heller’s grant was made possible in part by a generous donation from the Edmée Firth Fund for Research in Ovarian Cancer (EFFROC).

OCRA’s Advocate’s Corner

OCRA is pleased to welcome our largest Advocate Leaders cohort in history, with 125 participants representing 39 states and 111 congressional districts. Together we’re working to address drug shortages, broaden access to biomarker testing, expand genetic testing protections, and more. Get the latest from OCRA’s Advocate’s Corner and join us for virtual Spring Advocacy Day on March 20th.

New Support Series Workshops

OCRA is offering two special closed 12-week workshops. Advance registration is required to participate in these virtual sessions. 

Young Adults in Treatment

In this program for young adults diagnosed with gynecologic cancer, sessions will explore topics including careers, relationships, friendships, family life, ongoing treatment, and more. Registration ends on March 12th at 5pm ET.

Loved Ones Bereavement: Giving Voice to Grief

In this special session, attendees will explore issues facing caregivers and other family members who have lost a loved one to cancer. Registration closes March 20th at 5pm ET.

2025 Research Grant Cycle Opens

OCRA is pleased to announce we are now accepting Letters of Intent (LOIs) for our 2025 Grant Cycle. As the largest funder of ovarian cancer research in the world, OCRA is proud to enable pioneering research toward better treatments, prevention, equity in care, and ultimately a cure.

Posted on in OCRA News